IsoRay advances strongly for a second session, levels to watch Shares advanced strongly on Wednesday and in early trading today are up over 35% to $3.45. At that price next resistance is at $3.76. Support is at $2.99. On a long term chart the strong move up constitutes a long base breakout which are typically bullish for share price on a sustainable basis. The $2 area had been the top of the range extending back to 2009.
IsoRay selected by Chicago prostate cancer center for use in study IsoRay announced that Dr. Brian J. Moran, Director of Chicago Prostate Cancer Center in Westmont, Illinois, has initiated a study of focal prostate cancer treatment using Cesium-131 brachytherapy. Focal therapy is treatment directed solely at the malignancy and its immediate surrounding tissue, rather than the entire gland or organ that is involved. The goal of focal therapy for prostate cancer is to eliminate the targeted cancer while sparing men the side effects that often come with whole gland treatment.